The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC

BACKGROUND: Activation of the oncogene YAP has been shown to be related to lung cancer progression and associates with poor prognosis and metastasis. Metformin is a drug commonly used in the treatment of diabetes and with anticancer activity. However, the mechanism through which metformin inhibits t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Dan, Guo, Jiwei, Wang, Deqiang, Wu, Yan, Wang, Xiaohong, Gao, Yong, Shao, Cuijie, Xu, Xin, Tan, Shuying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284514/
https://www.ncbi.nlm.nih.gov/pubmed/30389502
http://dx.doi.org/10.1016/j.ebiom.2018.10.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284514/
https://www.ncbi.nlm.nih.gov/pubmed/30389502
http://dx.doi.org/10.1016/j.ebiom.2018.10.044

Ejemplares similares